Dipharma Francis Srl
Dipharma Francis Srl is an Italian privately held CDMO and API manufacturer serving pharmaceutical companies with two product lines: exclusive synthesis (custom process development and contract manufacturing) and catalogue APIs for the generic market.
- Company typePrivate
- Founded1949
- HeadquartersBaranzate, Italy
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dipharma Francis Srl does
Dipharma Francis Srl is a privately held Italian Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) manufacturer headquartered in the Milan metropolitan area (Baranzate), operating as a Società a responsabilità limitata with €8.4M fully paid-up share capital. The company runs two product lines: (i) CDMO-exclusive synthesis services providing custom route development, process optimization, and contract manufacturing for pharmaceutical clients, and (ii) catalogue APIs sold to the generic pharmaceutical market. Underlying capabilities are rooted in process chemistry rather than digital or AI technologies, anchored by 250+ patents, 40+ maintained quality standards, and a self-reported 75+ year operating history.
Dipharma Francis Srl firmographics
Firmographics- Name
- Dipharma Francis Srl
- Legal name
- Dipharma Francis Srl
- Website
- https://dipharma.it
- Company type
- Private
- Founded year
- 1949
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Dipharma Francis Srl is an Italian privately held CDMO and API manufacturer serving pharmaceutical companies with two product lines: exclusive synthesis (custom process development and contract manufacturing) and catalogue APIs for the generic market.
- Ownership category
- akta.pro rank
Dipharma Francis Srl industry classification
Industry- Product category
- Pharmaceutical API Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Lyophilization (Freeze-Drying) CDMO (HLAGABAI)
- akta.pro secondary industries
- Small-Molecule API Commercial Manufacturing (HLAGAHAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Dipharma Francis Srl is headquartered
LocationHeadquarters
- HQ city
- Baranzate
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Dipharma Francis Srl business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- CDMO Services: Contract Development and Manufacturing Organization services providing exclusive synthesis capabilities to pharmaceutical companies. Revenue derived from long-term manufacturing contracts and custom synthesis projects for drug development and commercial production.
- Catalogue APIs: Sale of Active Pharmaceutical Ingredients for generic pharmaceutical market. APIs are manufactured and sold to pharmaceutical companies for use in generic drug formulations.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Dipharma Francis Srl product offering
Product offeringCore offering
Dipharma Francis Srl is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops, optimizes, and manufactures Active Pharmaceutical Ingredients (APIs) under cGMP conditions for the global pharmaceutical industry. Its commercial offering is split between (1) exclusive synthesis services, providing custom process development and contract manufacturing of complex APIs for branded and generic drug developers, and (2) a catalogue of generic APIs produced at scale for use in finished generic drug formulations.
Product overview
Dipharma Francis Srl operates as a Global CDMO (Contract Development and Manufacturing Organization) and API manufacturer. The company offers two primary product lines: CDMO Services with Exclusive Synthesis capabilities, and Catalogue APIs for the generic market. With 75+ years of experience, 250+ patents, and 550+ employees, the company provides end-to-end pharmaceutical development and manufacturing services supporting clients through development and manufacturing while they focus on their ultimate goals.
Differentiator
Problem solved
Functional benefit
Products and services
- CDMO Services Contract Development and Manufacturing Organization services providing exclusive synthesis and manufacturing capabilities for pharmaceutical clients from clinical development through commercial supply.
- Exclusive Synthesis Custom synthesis services for complex pharmaceutical compounds, providing bespoke process development and small-to-commercial-scale API manufacturing for innovator and generic pharmaceutical clients.
- Catalogue APIs Active Pharmaceutical Ingredients (APIs) for the generic market, manufactured in-house at cGMP standards and supplied to generic drug manufacturers worldwide.
Companies that use Dipharma Francis Srl
Customer profileSegments1 record
Ideal customer profiles2 records
Dipharma Francis Srl technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Dipharma Francis Srl partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Dipharma Francis Srl competitors and assessment
Company assessmentBroad incumbents
- Cambrex: US/EU-based small-molecule API CDMO owned by Permira; comparable in exclusive synthesis and generic API offerings but with greater North American presence than Dipharma.
- Siegfried Holding: Swiss-listed CDMO with API and finished drug product manufacturing; larger, publicly-listed, and broader portfolio — overlapping with Dipharma's CDMO/API offering but at greater scale.
- Aenova Group: German pharmaceutical CDMO providing API and drug product services across solid dosage forms, sterile, and semi-solids; overlaps with Dipharma's API and exclusive synthesis services at a broader portfolio level.
Regional players
- PolyPeptide Group: Swiss-based CDMO specializing in peptide APIs; comparable contract manufacturing model though focused on a different molecule class than Dipharma's small-molecule focus.
Direct peers
- Olon S.p.A. Italian-headquartered API manufacturer offering both generic APIs and custom CDMO services; directly comparable in geography, business model, and product mix to Dipharma's CDMO + catalogue API structure.
- Fabbrica Italiana Sintetici (F.I.S.): Italian CDMO specializing in custom synthesis and API manufacturing for the pharmaceutical industry; competes head-to-head with Dipharma in exclusive synthesis and HPAPI services.
- Hovione: Portuguese-based global CDMO focused on API development and manufacturing, including particle engineering and integrated drug substance/drug product services; directly comparable scale and offering to Dipharma.
- CordenPharma: European-based CDMO offering API manufacturing and integrated drug product services across multiple modalities; competes with Dipharma in custom synthesis and pharmaceutical contract manufacturing.
- EuroAPI: French API manufacturer spun off from Sanofi, supplying both branded and generic APIs globally; competes with Dipharma's catalogue API business and offers CDMO services.
Emerging players
- Kalexsyn (Dipharma subsidiary): US-based custom synthesis CRO acquired by Dipharma in 2018; demonstrates Dipharma's transatlantic expansion and represents the company's own US-facing CDMO capability.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Dipharma Francis Srl social profiles
Digital presenceDipharma Francis Srl financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dipharma Francis Srl leadership team
Management profileNumber of profiles
Profiles2 records
Dipharma Francis Srl funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dipharma Francis Srl M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dipharma Francis Srl
What does Dipharma Francis Srl do?
Dipharma Francis Srl is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops, optimizes, and manufactures Active Pharmaceutical Ingredients (APIs) under cGMP conditions for the global pharmaceutical industry. Its commercial offering is split between (1) exclusive synthesis services, providing custom process development and contract manufacturing of complex APIs for branded and generic drug developers, and (2) a catalogue of generic APIs produced at scale for use in finished generic drug formulations.
Is Dipharma Francis Srl a public or private company?
Dipharma Francis Srl is a private company. It is classified as unknown and is currently operating.
When was Dipharma Francis Srl founded?
Dipharma Francis Srl was founded in 1949. It employs 501 to 1,000 people.
Where is Dipharma Francis Srl based?
Dipharma Francis Srl is headquartered in Baranzate, Italy, in the Europe region.
How does Dipharma Francis Srl make money?
Two revenue lines are on record. CDMO Services are the primary driver. The others are catalogue APIs.
Who are Dipharma Francis Srl's main competitors?
Broad incumbents on record are Cambrex, Siegfried Holding and Aenova Group. PolyPeptide Group is listed as a regional player. Direct peers are Olon S.p.A., Fabbrica Italiana Sintetici (F.I.S.), Hovione, CordenPharma and EuroAPI. Kalexsyn (Dipharma subsidiary) is listed as an emerging player.
Does Dipharma Francis Srl have an API?
No public API is recorded for Dipharma Francis Srl.
What industry is Dipharma Francis Srl in?
Dipharma Francis Srl's product category is Pharmaceutical API Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAI, Lyophilization (Freeze-Drying) CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.